NOVOZYMES A/S SPONS.ADR 1 (F:NZM) — Market Cap & Net Worth
Market Cap & Net Worth: NOVOZYMES A/S SPONS.ADR 1 (NZM)
NOVOZYMES A/S SPONS.ADR 1 (F:NZM) has a market capitalization of $24.08 Billion (€20.60 Billion) as of June 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #1113 globally and #250 in its home market, demonstrating a -0.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NOVOZYMES A/S SPONS.ADR 1's stock price €50.00 by its total outstanding shares 411941947 (411.94 Million). Review NZM total liabilities to assess the company's total debt and financial obligations.
NOVOZYMES A/S SPONS.ADR 1 Market Cap History: 2021 to 2026
NOVOZYMES A/S SPONS.ADR 1's market capitalization history from 2021 to 2026. Data shows change from $32.08 Billion to $24.56 Billion (-5.73% CAGR).
NOVOZYMES A/S SPONS.ADR 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NOVOZYMES A/S SPONS.ADR 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.20x
NOVOZYMES A/S SPONS.ADR 1's market cap is 6.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
44.15x
NOVOZYMES A/S SPONS.ADR 1's market cap is 44.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $32.08 Billion | $2.01 Billion | $423.00 Million | 15.96x | 75.84x |
| 2022 | $21.35 Billion | $2.36 Billion | $493.36 Million | 9.06x | 43.28x |
| 2023 | $23.44 Billion | $2.40 Billion | $405.90 Million | 9.76x | 57.76x |
| 2024 | $26.01 Billion | $3.83 Billion | $305.80 Million | 6.78x | 85.04x |
| 2025 | $25.77 Billion | $4.16 Billion | $583.60 Million | 6.20x | 44.15x |
Competitor Companies of NZM by Market Capitalization
Companies near NOVOZYMES A/S SPONS.ADR 1 in the global market cap rankings as of June 17, 2026.
Key companies related to NOVOZYMES A/S SPONS.ADR 1 by market ranking:
- Linde plc Ordinary Shares (NASDAQ:LIN): Ranked #95 globally with a market cap of $210.18 Billion USD.
- AIR LIQUIDE ADR 1/5/EO 11 (F:AILA): Ranked #243 globally with a market cap of $103.86 Billion USD ( €88.84 Billion EUR).
- Air Liquide SA (PA:AI): Ranked #253 globally with a market cap of $101.06 Billion USD ( €86.44 Billion EUR).
- Sherwin-Williams Co (NYSE:SHW): Ranked #333 globally with a market cap of $79.39 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #95 | Linde plc Ordinary Shares | NASDAQ:LIN | $210.18 Billion | $521.48 |
| #243 | AIR LIQUIDE ADR 1/5/EO 11 | F:AILA | $103.86 Billion | €36.60 |
| #253 | Air Liquide SA | PA:AI | $101.06 Billion | €165.86 |
| #333 | Sherwin-Williams Co | NYSE:SHW | $79.39 Billion | $320.24 |
NOVOZYMES A/S SPONS.ADR 1 Historical Marketcap From 2021 to 2026
Between 2021 and today, NOVOZYMES A/S SPONS.ADR 1's market cap moved from $32.08 Billion to $ 24.56 Billion, with a yearly change of -5.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €24.56 Billion | -4.67% |
| 2025 | €25.77 Billion | -0.93% |
| 2024 | €26.01 Billion | +10.93% |
| 2023 | €23.44 Billion | +9.79% |
| 2022 | €21.35 Billion | -33.44% |
| 2021 | €32.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of NOVOZYMES A/S SPONS.ADR 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.08 Billion USD |
| MoneyControl | $24.08 Billion USD |
| MarketWatch | $24.08 Billion USD |
| marketcap.company | $24.08 Billion USD |
| Reuters | $24.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NOVOZYMES A/S SPONS.ADR 1
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as protein solutions and … Read more